A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe Chronic Obstructive Pulmonary Disease（COPD）. The study has two parts. Each part consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 8-week safety follow-up period.

Timeline

Start

2024-09-13

Primary completion

2032-04-29

Completion

2032-10-31

Drugs

Indications